CD4+ Th1 Cells Promote CD8+ Tc1 Cell Survival, Memory Response, Tumor Localization and Therapy by Targeted Delivery of Interleukin 2 Via Acquired PMHC I Complexes

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2007 Feb 3

PMID 17274112

Citations 40

Authors

Hui Huang

Siguo Hao

Fang Li

Zhenmin Ye

Junbao Yang

Jim Xiang

Affiliations

Soon will be listed here.

Abstract

The cooperative role of CD4+ helper T (Th) cells has been reported for CD8+ cytotoxic T (Tc) cells in tumor eradication. However, its molecular mechanisms have not been well elucidated. We have recently demonstrated that CD4+ Th cells can acquire major histocompatibility complex/peptide I (pMHC I) complexes and costimulatory molecules by dendritic cell (DC) activation, and further stimulate naïve CD8+ T cell proliferation and activation. In this study, we used CD4+ Th1 and CD8+ Tc1 cells derived from ovalbumin (OVA)-specific T cell receptor (TCR) transgenic OT II and OT I mice to study CD4+ Th1 cell's help effects on active CD8+ Tc1 cells and the molecular mechanisms involved in CD8+ Tc1-cell immunotherapy of OVA-expressing EG7 tumors. Our data showed that CD4+ Th1 cells with acquired pMHC I by OVA-pulsed DC (DCOVA) stimulation are capable of prolonging survival and reducing apoptosis formation of active CD8+ Tc1 cells in vitro, and promoting CD8+ Tc1 cell tumor localization and memory responses in vivo by 3-folds. A combined adoptive T-cell therapy of CD8+ Tc1 with CD4+ Th1 cells resulted in regression of well-established EG7 tumors (5 mm in diameter) in all 10/10 mice. The CD4+ Th1's help effect is mediated via the helper cytokine IL-2 specifically targeted to CD8+ Tc1 cells in vivo by acquired pMHC I complexes. Taken together, these results will have important implications for designing adoptive T-cell immunotherapy protocols in treatment of solid tumors.

Citing Articles

Single-cell RNA sequencing unveils the hidden powers of zebrafish kidney for generating both hematopoiesis and adaptive antiviral immunity.

Hu C, Zhang N, Hong Y, Tie R, Fan D, Lin A Elife. 2024; 13.

PMID: 38497789 PMC: 10948150. DOI: 10.7554/eLife.92424.

VAX014, an Oncolytic Therapy, Reduces Adenomas and Modifies Colon Microenvironment in Mouse Model of CRC.

Grenier S, Khan M, Reil K, Sawaged S, Tsuji S, Giacalone M Int J Mol Sci. 2023; 24(12).

PMID: 37373142 PMC: 10298379. DOI: 10.3390/ijms24129993.

The Microbiome-TIME Axis: A Host of Possibilities.

Ross T, Zhang J Microorganisms. 2023; 11(2).

PMID: 36838253 PMC: 9965696. DOI: 10.3390/microorganisms11020288.

Immunotherapy as a potential treatment approach for currently incurable bone metastasis.

Yu Y, Ollodart J, Contino K, Shiozawa Y J Bone Miner Metab. 2023; 41(3):371-379.

PMID: 36752903 PMC: 10251738. DOI: 10.1007/s00774-023-01404-3.

Cellular senescence-related long noncoding ribonucleic acids: Predicting prognosis in hepatocellular carcinoma.

Huang H, Yao H, Wei Y, Chen M, Sun J Cancer Rep (Hoboken). 2023; 6(4):e1791.

PMID: 36726348 PMC: 10075286. DOI: 10.1002/cnr2.1791.

References

Vella A, Mitchell T, Groth B, Linsley P, Green J, Thompson C . CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol. 1997; 158(10):4714-20. View

Carter L, Dutton R . Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol. 1996; 8(3):336-42. DOI: 10.1016/s0952-7915(96)80122-1. View

Dutton R, Bradley L, Swain S . T cell memory. Annu Rev Immunol. 1998; 16:201-23. DOI: 10.1146/annurev.immunol.16.1.201. View

Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393(6684):478-80. DOI: 10.1038/30996. View

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H . CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58(16):3491-4. View

Fernando G, Stewart T, Tindle R, Frazer I . Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. J Immunol. 1998; 161(5):2421-7. View

Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A . T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science. 1999; 283(5402):680-2. DOI: 10.1126/science.283.5402.680. View

Marzo A, Lake R, Robinson B, Scott B . T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 1999; 59(5):1071-9. View

Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E . Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol. 1999; 162(6):3574-82. View

10.

Ogawa M, Umehara K, Yu W, Uekusa Y, Nakajima C, Tsujimura T . A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res. 1999; 59(7):1531-8. View

11.

Dobrzanski M, Reome J, Dutton R . Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J Immunol. 1999; 162(11):6671-80. View

12.

Lenardo M, Chan K, Hornung F, McFarland H, Siegel R, Wang J . Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999; 17:221-53. DOI: 10.1146/annurev.immunol.17.1.221. View

13.

Kjaergaard J, Shu S . Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol. 1999; 163(2):751-9. View

14.

Grakoui A, Bromley S, Sumen C, Davis M, Shaw A, Allen P . The immunological synapse: a molecular machine controlling T cell activation. Science. 1999; 285(5425):221-7. DOI: 10.1126/science.285.5425.221. View

15.

Kennedy R, Undale A, Kieper W, Block M, Pease L, Celis E . Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses. J Immunol. 2005; 174(7):3967-77. DOI: 10.4049/jimmunol.174.7.3967. View

16.

Huang H, Bi X, Yuan J, Xu S, Guo X, Xiang J . Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy. Gene Ther. 2005; 12(12):999-1010. DOI: 10.1038/sj.gt.3302486. View

17.

Xiang J, Huang H, Liu Y . A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J Immunol. 2005; 174(12):7497-505. DOI: 10.4049/jimmunol.174.12.7497. View

18.

Brandes M, Willimann K, Moser B . Professional antigen-presentation function by human gammadelta T Cells. Science. 2005; 309(5732):264-8. DOI: 10.1126/science.1110267. View

19.

Porgador A, Yewdell J, Deng Y, Bennink J, Germain R . Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity. 1997; 6(6):715-26. DOI: 10.1016/s1074-7613(00)80447-1. View

20.

Mosmann T, Sad S . The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996; 17(3):138-46. DOI: 10.1016/0167-5699(96)80606-2. View